DDInter1802 DDInter782
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Ticagrelor {u} (Compound) treats {v} (Disease) coronary artery disease
Ticagrelor {u} (Compound) binds {v} (Gene) ABCB1
Ticagrelor {u} (Compound) is included by {v} (Pharmacologic Class) Phenylalanine Hydroxylase Activators
Ticagrelor {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nifedipine
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lepirudin
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Indinavir
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Ticagrelor (Compound) treats coronary artery disease (Disease)
Ticagrelor (Compound) binds ABCB1 (Gene)
Ticagrelor (Compound) is included by Phenylalanine Hydroxylase Activators (Pharmacologic Class)
Ticagrelor (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ticagrelor may lead to a major life threatening interaction when taken with Indinavir
Ticagrelor may lead to a major life threatening interaction when taken with Relugolix